Trastuzumab, a monoclonal antibody for cancers with large amounts of human epidermal growth factor receptor 2 (HER2), provides the best example of type II CTRCD where the myocardial damage is not considered to be cumulative, dose-dependent, or progressive. This evidence concerns the gene ERBB2 and cancer.